10/574,119

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:42:08 ON 20 AUG 2008

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 10:42:21 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Aug 2008 VOL 149 ISS 8
FILE LAST UPDATED: 19 Aug 2008 (20080819/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 165537-73-5 and clopidogrel
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L2 14 L1

2230 CLOPIDOGREL
L3 2 L2 AND CLOPIDOGREL

=> d 1-2 ibib abs hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:301861 CAPLUS
DOCUMENT NUMBER: 142:329857
TITLE: Synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor
INVENTOR(S): Cloarec, Blanchard Laure; Corda, Stefano; Lerond, Laurence
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: Fr. Demande, 10 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2860436	A1	20050408	FR 2003-11595	20031003
FR 2860436	B1	20060120		
AU 2004277734	A1	20050414	AU 2004-277734	20041001
AU 2004277734	B2	20070524		
CA 2540062	A1	20050414	CA 2004-2540062	20041001
WO 2005032533	A1	20050414	WO 2004-FR2489	20041001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1677779	A1	20060712	EP 2004-791453	20041001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1859902	A	20061108	CN 2004-80028356	20041001
BR 2004015043	A	20061212	BR 2004-15043	20041001
JP 2007507475	T	20070329	JP 2006-530412	20041001
IN 2006DN01446	A	20070803	IN 2006-DN1446	20060317
US 20070054934	A1	20070308	US 2006-574119	20060330
MX 2006PA03713	A	20060614	MX 2006-PA3713	20060403
KR 782246	B1	20071205	KR 2006-708071	20060426
NO 2006001944	A	20060502	NO 2006-1944	20060502
PRIORITY APPLN. INFO.:			FR 2003-11595 A	20031003
			WO 2004-FR2489 W	20041001

AB A new synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor is claimed. Combination of 75 mg clopidogrel and 10 mg of 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl-1-naphthalenepropanoic acid administered orally to volunteers for 3 days decreased the platelet aggregation by 62% as compared to 11% for clopidogrel alone.
IT 165537-73-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(synergistic combination of anti-atherothrombotic agent and platelet aggregation inhibitor)

RN 165537-73-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:405522 CAPLUS

DOCUMENT NUMBER: 141:374569

TITLE: Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist

AUTHOR(S): Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.; Badimon, J. J.

CORPORATE SOURCE: Cardiovascular Biology Research Laboratory and Cardiovascular Institute, Mount Sinai School of Medicine, New York City, NY, USA

SOURCE: Journal of Thrombosis and Haemostasis (2004), 2(3), 492-498
CODEN: JTHOA5; ISSN: 1538-7933

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Platelet activation and thrombus formation play a critical role in the onset of acute coronary syndromes. Thromboxane A2 (TxA2) is among the different chemical modulators released by activated platelets. TxA2 is considered one of the most powerful agonists for platelet activation. In addition, TxA2 exerts a vasoconstrictor effect by serving as an agonist of the thromboxane receptor (TP) on the vascular smooth muscle cell membranes. The putative effect of TxA2 on thrombosis is demonstrated by the clin. effectiveness of acetylsalicylic acid (ASA) in the prevention of acute coronary syndromes. Among the clin. used antiplatelet agents, clopidogrel has shown to be slightly more effective than ASA in the prevention of atherothrombotic events in patients with peripheral arterial disease, and is one of the most widely used after aspirin. The aims of the study were to study the antithrombotic effects of escalating doses of the TP-receptor antagonist, S 18886 and to compare its effects with those achieved by the administration of ASA (5 mg kg-1 day-1), and clopidogrel (3 mg kg-1 day-1). The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic effects were assessed as changes on platelet and fibrin(ogen) deposition. The doses of 30 and 100 μg kg-1 day-1 were selected based on a previous platelet aggregation study. S

18886 shows a dose-dependent antithrombotic response. The dose of S-100 develops similar antithrombotic effects to those of clopidogrel and superior to those of aspirin. The antithrombotic effects were statistically significant at both studied shear rate conditions. Therefore, the orally active TP-receptor antagonist, S 18886, appears to be a new and effective agent to prevent atherothrombotic complications.

IT 165537-73-5, S 18886
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TP-receptor antagonist S 18886 at 100μg/kg/day exerted dose-dependent antithrombotic effect similar to clopidogrel but superior to ASA at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)

RN 165537-73-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.10	17.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 10:44:11 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3
DICTIONARY FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s  clopidogrel/cn
L4           1 CLOPIDOGREL/CN

=> d

L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   113665-84-2  REGISTRY
ED   Entered STN:  02 Apr 1988
CN   Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-
     dihydro-, methyl ester, (αS)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-
     dihydro-, methyl ester, (S)-
OTHER NAMES:
CN   (+)-(S)-Clopidogrel
CN   (S)-(+)-Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-
     yl)acetate
CN   (S)-Clopidogrel
CN   (S)-Methyl α-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-α-
     (o-chlorophenyl)acetate
CN   Clopidogrel
CN   Methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-
     yl)acetate
CN   SR 25990
CN   Zyllt
FS   STEREOSEARCH
MF   C16 H16 Cl N O2 S
CI   COM
SR   World Health Organization (WHO)
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, EMBASE, HSDB*,
       IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC,
       PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.  Rotation (+).
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1642 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1656 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.07	25.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 10:45:18 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Aug 2008 VOL 149 ISS 8
FILE LAST UPDATED: 19 Aug 2008 (20080819/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 165537-73-5 and 113665-84-2
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6 1656 L5

REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L8 14 L7

L9 2 L8 AND L6

=> d 1-2 ibib abs hitstr

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:301861 CAPLUS
DOCUMENT NUMBER: 142:329857
TITLE: Synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor
INVENTOR(S): Cloarec, Blanchard Laure; Corda, Stefano; Lerond, Laurence
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: Fr. Demande, 10 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2860436	A1	20050408	FR 2003-11595	20031003
FR 2860436	B1	20060120		
AU 2004277734	A1	20050414	AU 2004-277734	20041001
AU 2004277734	B2	20070524		
CA 2540062	A1	20050414	CA 2004-2540062	20041001
WO 2005032533	A1	20050414	WO 2004-FR2489	20041001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1677779	A1	20060712	EP 2004-791453	20041001

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CN	1859902	A	20061108	CN	2004-80028356		20041001
BR	2004015043	A	20061212	BR	2004-15043		20041001
JP	2007507475	T	20070329	JP	2006-530412		20041001
IN	2006DN01446	A	20070803	IN	2006-DN1446		20060317
US	20070054934	A1	20070308	US	2006-574119		20060330
MX	2006PA03713	A	20060614	MX	2006-PA3713		20060403
KR	782246	B1	20071205	KR	2006-708071		20060426
NO	2006001944	A	20060502	NO	2006-1944		20060502
PRIORITY APPLN. INFO.:				FR	2003-11595	A	20031003
				WO	2004-FR2489	W	20041001

AB A new synergistic combination of an anti-atherothrombotic agent and a platelet aggregation inhibitor is claimed. Combination of 75 mg clopidogrel and 10 mg of 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl-1-naphthalenepropanoic acid administered orally to volunteers for 3 days decreased the platelet aggregation by 62% as compared to 11% for clopidogrel alone.

IT 113665-84-2, Clopidogrel 165537-73-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic combination of anti-atherothrombotic agent and platelet aggregation inhibitor)

RN 113665-84-2 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 165537-73-5 CAPLUS

CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:405522 CAPLUS
DOCUMENT NUMBER: 141:374569
TITLE: Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist
AUTHOR(S): Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.; Badimon, J. J.
CORPORATE SOURCE: Cardiovascular Biology Research Laboratory and Cardiovascular Institute, Mount Sinai School of Medicine, New York City, NY, USA
SOURCE: Journal of Thrombosis and Haemostasis (2004), 2(3), 492-498
CODEN: JTHOA5; ISSN: 1538-7933
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Platelet activation and thrombus formation play a critical role in the onset of acute coronary syndromes. Thromboxane A2 (TxA2) is among the different chemical modulators released by activated platelets. TxA2 is considered one of the most powerful agonists for platelet activation. In addition, TxA2 exerts a vasoconstrictor effect by serving as an agonist of the thromboxane receptor (TP) on the vascular smooth muscle cell membranes. The putative effect of TxA2 on thrombosis is demonstrated by the clin. effectiveness of acetylsalicylic acid (ASA) in the prevention of acute coronary syndromes. Among the clin. used antiplatelet agents, clopidogrel has shown to be slightly more effective than ASA in the prevention of atherothrombotic events in patients with peripheral arterial disease, and is one of the most widely used after aspirin. The aims of the study were to study the antithrombotic effects of escalating doses of the TP-receptor antagonist, S 18886 and to compare its effects with those achieved by the administration of ASA (5 mg kg-1 day-1), and clopidogrel (3 mg kg-1 day-1). The study was undertaken at high and low shear rate conditions using the Badimon perfusion chamber in a porcine model. Antithrombotic effects were assessed as changes on platelet and fibrin(ogen) deposition. The doses of 30 and 100 μg kg-1 day-1 were selected based on a previous platelet aggregation study. S 18886 shows a dose-dependent antithrombotic response. The dose of S-100 develops similar antithrombotic effects to those of clopidogrel and superior to those of aspirin. The antithrombotic effects were statistically significant at both studied shear rate conditions. Therefore, the orally active TP-receptor antagonist, S 18886, appears to be a new and effective agent to prevent atherothrombotic complications.

IT 165537-73-5, S 18886
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TP-receptor antagonist S 18886 at 100μg/kg/day exerted dose-dependent antithrombotic effect similar to clopidogrel but superior to ASA at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)

RN 165537-73-5 CAPLUS
CN 1-Naphthalenepropanoic acid, 6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



IT 113665-84-2, Clopidogrel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral TP-receptor antagonist S 18886 at 100μg/kg/day exerted dose-dependent antithrombotic effect similar to clopidogrel at high, low shear rates as evident by inhibition of platelet and fibrinogen deposition in pig model)
RN 113665-84-2 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT